The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 14, 2021

Filed:

Sep. 02, 2020
Applicants:

Arizona Board of Regents on Behalf of Arizona State University, Scottsdale, AZ (US);

Oncomyx Therapeutics, Inc., Phoenix, AZ (US);

Inventors:

Douglas Grant McFadden, Tempe, AZ (US);

Mohammed Masmudur Rahman, Chandler, AZ (US);

Nancy Villa, Tempe, AZ (US);

Lino Torres-Dominguez, Tempe, AZ (US);

Lina Franco Achury, Tempe, AZ (US);

Leslie Lynne Sharp, Rancho Santa Fe, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/065 (2006.01); C07K 14/005 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); A61P 35/04 (2006.01); A61K 45/06 (2006.01); A61K 39/275 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/275 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 14/525 (2013.01); C07K 14/5434 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C07K 2319/33 (2013.01); C12N 2710/24022 (2013.01); C12N 2710/24033 (2013.01); C12N 2710/24071 (2013.01);
Abstract

Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.


Find Patent Forward Citations

Loading…